Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin�s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia

Phase I part:� - To assess the MTD and the dose-limiting toxicities (DLTs).� Phase II part: - To assess the objective response rate at the recommended dose defined in the phase I part.� - To assess the safety and tolerability.